NASDAQ:NVCNNeovasc Stock Price, Forecast & News

Neovasc's stock was trading at $2.21 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NVCN shares have increased by 9.0% and is now trading at $2.41. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neovasc.

Neovasc is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Neovasc.

Neovasc Inc (NASDAQ:NVCN) posted its earnings results on Thursday, May, 7th. The medical equipment provider reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.17. The medical equipment provider had revenue of $0.53 million for the quarter, compared to the consensus estimate of $0.60 million. View Neovasc's earnings history.

Neovasc's stock reverse split on Friday, September 21st 2018. The 1-100 reverse split was announced on Tuesday, September 11th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 20th 2018. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 1 shares after the split.

Neovasc issued an update on its second quarter 2020 IntraDay earnings guidance on Monday, July, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $295K - 295K.

3 brokers have issued 12 month price objectives for Neovasc's shares. Their forecasts range from $3.00 to $15.00. On average, they anticipate Neovasc's share price to reach $7.67 in the next twelve months. This suggests a possible upside of 218.1% from the stock's current price. View analysts' price targets for Neovasc.

Media coverage about NVCN stock has trended negative on Wednesday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neovasc earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Neovasc.

Neovasc saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 210,600 shares, a drop of 14.1% from the May 31st total of 245,300 shares. Based on an average daily trading volume, of 216,500 shares, the short-interest ratio is currently 1.0 days. Approximately 1.9% of the company's shares are short sold. View Neovasc's Current Options Chain.

Some companies that are related to Neovasc include PAVmed (PAVM), Spectral Medical (EDTXF), SANUWAVE Health (SNWV), Nephros (NEPH), AIT Therapeutics (AITB), Pro-Dex (PDEX), BRAINSWAY LTD/S (BWAY), Nephros (NEPHD), Titan Medical (TMDI), Sensus Healthcare (SRTS), Motus GI (MOTS), STRATA Skin Sciences (SSKN), Neuronetics (STIM), Apollo Endosurgery (APEN) and Atossa Genetics (ATOS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Rexahn Pharmaceuticals (REXN), Synergy Pharmaceuticals (SGYP), Amicus Therapeutics (FOLD), Protalix Biotherapeutics (PLX), 22nd Century Group (XXII), Immune Pharmaceuticals (IMNP), Advanced Micro Devices (AMD) and Amarin (AMRN).

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCN stock can currently be purchased for approximately $2.41.

Neovasc has a market capitalization of $26.83 million and generates $2.09 million in revenue each year. The medical equipment provider earns $-35,130,000.00 in net income (profit) each year or ($5.05) on an earnings per share basis. Neovasc employs 98 workers across the globe.

The official website for Neovasc is www.neovasc.com.

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-248-4138 or via email at [email protected]